19 Aug, 2023

Mind Matters with Dr Greg Mattingly

Dr Gregory Mattingly discusses in this series of interview vignettes his clinical and academic experience with Brintellix® (vortioxetine) in the treatment of adults with major depressive disorder.1

These vignettes demonstrate Dr Mattingly’s evidence-based management approach to the application of Brintellix® data to real-world case studies.

31 Oct, 2023

Think Depression. Think Brintellix®

28 Jul, 2023

Clinical experience in treating MDD patients with Brintellix® (vortioxetine) (1)

01 Aug, 2023

Treating the broad spectrum of depressive symptoms

01 Aug, 2023

Treating MDD patients with an inadequate response to prior treatment with an SSRI/SNRI

References

  1. Brintellix® (vortioxetine) Australian Approved Product Information

The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

Internal ID: AU-BRIN-0645. September 2023

  • Brintellix
    Body

    Brintellix PBS information: This product is not listed on the PBS.

  • footer text
    Body

    Please review Approved Product Information before prescribing.
    Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:

    Brintellix PI

    Brintellix is a registered trademark of H. Lundbeck A/S.

Related

GO TO

Contributor

Dr Gregory W. Mattingly
MD, Associate Professor Washington University School of Medicine President, Midwest Group, St. Louis, Missouri, USA

BROUGHT TO YOU BY

Lundbeck
© 2022 Lundbeck Australia

LUNDBECK AUSTRALIA PRODUCTS

Privacy and disclaimer

Cookies

Contact Us

Lundbeck Australia Pty Ltd 
1 Innovation road, Ground floor
NSW 2113, North Ryde, Australia
Phone +61 2 8669 1000
Fax +61 2 8669 1090

 

subscribe newsletter

Sign up for newsletter

This website is intended for viewing only by health care professionals in Australia.

All information provided within this site is intended only for residents of Australia.